Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext ScienceFRA:VV5 +2.53%53 Debt-to-Equity is 0.62 as of Jun. 2026, which is 41% above its 10-year median of 0.44. GuruFocus rates FRA:VV5 with a GF Score™ of 53/100 and a GF Value™ of €0.16 (Fairly Valued). The stock has 4 warning signs investors should review. Among 810 Drug Manufacturers companies, Vext Science ranks worse than 75.68% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vext Science's Debt-to-Equity or its related term are showing as below:
FRA:VV5'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.44 Max: 0.63
Current: 0.62
During the past 9 years, the highest Debt-to-Equity Ratio of Vext Science was 0.63. The lowest was 0.07. And the median was 0.44.
FRA:VV5's Debt-to-Equity is ranked worse than 75.68% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs FRA:VV5: 0.62
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vext Science Debt-to-Equity Related Terms
Vext Science Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vext Science's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vext Science's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a Debt-to-Equity of 0.62 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vext Science and its competitors. This is 41% above median its historical median of 0.44. Over the past decade, Vext Science's Debt-to-Equity has ranged from 0.07 to 0.63. According to the industry distribution chart, Vext Science ranks #613 out of 810 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is Vext Science's Debt-to-Equity too high?
Vext Science's current Debt-to-Equity of 0.62 is 41% above median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.63. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Vext Science's value of 0.62 is 121.4% above this industry median. Based on the distribution chart, Vext Science ranks #613 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #613 out of 810 companies for Debt-to-Equity. This places Vext Science in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Vext Science's value of 0.62 is 121.4% above this benchmark. Historically, Vext Science's own Debt-to-Equity has ranged from 0.07 to 0.63 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.28, Vext Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current Debt-to-Equity of 0.62 is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Debt-to-Equity is 0.62, which is 41% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (FRA:VV5) is currently considered Fairly Valued. The stock's GF Value™ is €0.16, compared to a current price of €0.16 — trading 1.3% above its estimated fair value. The current Debt-to-Equity is 0.62, which is 41% above median its 10-year median of 0.44 and 121.4% above the Drug Manufacturers industry median of 0.28. Vext Science's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Debt-to-Equity is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be overvalued.
The current stock price of €0.16 is trading 1.3% above its estimated GF Value™ of €0.16.
GuruFocus considers Vext Science to be Fairly Valued.
Key valuation signals for FRA:VV5:
Debt-to-Equity: 0.62 (41% above median its 10-year median of 0.44)
GF Value™: €0.16 vs. price of €0.16 (1.3% above fair value)
Industry Position: 121.4% above the Drug Manufacturers median (#613 of 810)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
53GF Score
Get the complete analysis for FRA:VV5
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
